Pharma BD Deal Intelligence

Horizon Pharma plc / Hyperion Therapeutics, Inc.

2015 · Acquisition/Merger · $1.1B · Complete

Announcement Sentiment

Strongly positive

Horizon Pharma acquired Hyperion Therapeutics for $46/share or approximately $1.1B in cash, adding Ravicti and Buphenyl for urea cycle disorders to Horizon's rare disease portfolio.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced May 07, 2015
Closed May 07, 2015
Deal value $1.1B
Deal type Acquisition/Merger
Therapeutic area Urea cycle disorders (UCD)
Indications Urea cycle disorders (UCD)
Key assets Ravicti (glycerol phenylbutyrate); Buphenyl (sodium phenylbutyrate)
Mechanism Nitrogen-binding agents — alternate ammonia-scavenging pathway

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals